Nature Reviews Cardiology最新文献_第7页

Insights into endothelial metabolic heterogeneity 洞察内皮代谢异质性。

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-06-05 DOI: 10.1038/s41569-024-01049-3

Corey McAleese

引用次数: 0

Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications 心房颤动的代谢重塑：表现、机制和临床意义。

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-05-30 DOI: 10.1038/s41569-024-01038-6

David Bode, Julius Ryan D. Pronto, Gabriele G. Schiattarella, Niels Voigt

{"title":"Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications","authors":"David Bode, Julius Ryan D. Pronto, Gabriele G. Schiattarella, Niels Voigt","doi":"10.1038/s41569-024-01038-6","DOIUrl":"10.1038/s41569-024-01038-6","url":null,"abstract":"Atrial fibrillation (AF) is a continually growing health-care burden that often presents together with metabolic disorders, including diabetes mellitus and obesity. Current treatments often fall short of preventing AF and its adverse outcomes. Accumulating evidence suggests that metabolic disturbances can promote the development of AF through structural and electrophysiological remodelling, but the underlying mechanisms that predispose an individual to AF are aetiology-dependent, thus emphasizing the need for tailored therapeutic strategies to treat AF that target an individual’s metabolic profile. AF itself can induce changes in glucose, lipid and ketone metabolism, mitochondrial function and myofibrillar energetics (as part of a process referred to as ‘metabolic remodelling’), which can all contribute to atrial dysfunction. In this Review, we discuss our current understanding of AF in the setting of metabolic disorders, as well as changes in atrial metabolism that are relevant to the development of AF. We also describe the potential of available and emerging treatment strategies to target metabolic remodelling in the setting of AF and highlight key questions and challenges that need to be addressed to improve outcomes in these patients. In this Review, the authors describe the changes in metabolism that predispose individuals to developing atrial fibrillation (AF) and highlight the potential of available and emerging therapeutic strategies that target metabolic remodelling to treat AF.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 10","pages":"682-700"},"PeriodicalIF":41.7,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A distinct platelet differentiation pathway is involved in age-related thrombocytosis 与年龄相关的血小板增多症涉及一种独特的血小板分化途径。

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-05-29 DOI: 10.1038/s41569-024-01043-9

Karina Huynh

引用次数: 0

Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF 在预防充血性高血压方面，减肥代谢手术比 GLP1R 激动剂更有效。

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-05-28 DOI: 10.1038/s41569-024-01042-w

Irene Fernández-Ruiz

引用次数: 0

Aficamten reduces symptoms in obstructive hypertrophic cardiomyopathy Aficamten 可减轻阻塞性肥厚型心肌病的症状。

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-05-28 DOI: 10.1038/s41569-024-01044-8

Gregory B. Lim

引用次数: 0

Artificially transplanted mitochondria in endothelial cells promote mitophagy 内皮细胞中人工移植的线粒体可促进有丝分裂。

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-05-21 DOI: 10.1038/s41569-024-01041-x

Karina Huynh

引用次数: 0

Bile acid receptor protects against diabetic cardiomyopathy 胆汁酸受体可预防糖尿病心肌病

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-05-20 DOI: 10.1038/s41569-024-01040-y

Irene Fernández-Ruiz

引用次数: 0

Efferocytosis in atherosclerosis 动脉粥样硬化中的吞噬作用

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-05-15 DOI: 10.1038/s41569-024-01037-7

Shaunak S. Adkar, Nicholas J. Leeper

{"title":"Efferocytosis in atherosclerosis","authors":"Shaunak S. Adkar, Nicholas J. Leeper","doi":"10.1038/s41569-024-01037-7","DOIUrl":"10.1038/s41569-024-01037-7","url":null,"abstract":"Cardiovascular disease is the leading cause of death worldwide, and it commonly results from atherosclerotic plaque progression. One of the increasingly recognized drivers of atherosclerosis is dysfunctional efferocytosis, a homeostatic mechanism responsible for the clearance of dead cells and the resolution of inflammation. In atherosclerosis, the capacity of phagocytes to participate in efferocytosis is hampered, leading to the accumulation of apoptotic and necrotic tissue within the plaque, which results in enlargement of the necrotic core, increased luminal stenosis and plaque inflammation, and predisposition to plaque rupture or erosion. In this Review, we describe the different forms of programmed cell death that can occur in the atherosclerotic plaque and highlight the efferocytic machinery that is normally implicated in cardiovascular physiology. We then discuss the mechanisms by which efferocytosis fails in atherosclerosis and other cardiovascular and cardiometabolic diseases, including myocardial infarction and diabetes mellitus, and discuss therapeutic approaches that might reverse this pathological process. In this Review, Adkar and Leeper describe the mechanisms of programmed cell death and efferocytosis, discuss how efferocytosis becomes impaired in atherosclerosis and other cardiometabolic diseases, and suggest potential strategies to target these pathways for the treatment of atherosclerotic cardiovascular disease.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 11","pages":"762-779"},"PeriodicalIF":41.7,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41569-024-01037-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140925028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention? 血管再通的假象：是否有人在经皮冠状动脉介入治疗过程中实现了最佳血管再通？

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-05-07 DOI: 10.1038/s41569-024-01014-0

Simone Fezzi, Daixin Ding, Felix Mahfoud, Jiayue Huang, Alexandra J. Lansky, Shengxian Tu, William Wijns

{"title":"Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?","authors":"Simone Fezzi, Daixin Ding, Felix Mahfoud, Jiayue Huang, Alexandra J. Lansky, Shengxian Tu, William Wijns","doi":"10.1038/s41569-024-01014-0","DOIUrl":"10.1038/s41569-024-01014-0","url":null,"abstract":"This Perspective article is a form of ‘pastiche’, inspired by the 1993 review by Lincoff and Topol entitled ‘Illusion of reperfusion’, and explores how their concept continues to apply to percutaneous revascularization in patients with coronary artery disease and ischaemia. Just as Lincoff and Topol argued that reperfusion of acute myocardial infarction was facing unresolved obstacles that hampered clinical success in 1993, we propose that challenging issues are similarly jeopardizing the potential benefits of stent-based angioplasty today. By analysing the appropriateness and efficacy of percutaneous coronary intervention (PCI), we emphasize the limitations of relying solely on visual angiographic guidance, which frequently leads to inappropriate stenting and overtreatment in up to one-third of patients and the associated increased risk of periprocedural myocardial infarction. The lack of optimal revascularization observed in half of patients undergoing PCI confers risks such as suboptimal physiology after PCI, residual angina and long-term stent-related events, leaving an estimated 76% of patients with an ‘illusion of revascularization’. These outcomes highlight the need to refine our diagnostic tools by integrating physiological assessments with targeted intracoronary imaging and emerging strategies, such as co-registration systems and angiography-based computational methods enhanced by artificial intelligence, to achieve optimal revascularization outcomes. In 1993, Lincoff and Topol claimed that the thrombolytic treatment of ST-segment elevation myocardial infarction was suboptimal in many patients and gave an ‘illusion of reperfusion’. In this Perspective article, the authors propose that a similar illusion of revascularization exists for contemporary percutaneous revascularization in patients with coronary artery disease and ischaemia, and identify how outcomes might be improved.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 9","pages":"652-662"},"PeriodicalIF":41.7,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140845335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

No benefit of apoA-I infusion after myocardial infarction 心肌梗死后输注载脂蛋白 A-I 无益

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-05-03 DOI: 10.1038/s41569-024-01031-z

Gregory B. Lim

引用次数: 0